Lv4
450 积分 2021-09-16 加入
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
Head and Neck Cancer
4个月前
已完结
Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer
4个月前
已完结
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
4个月前
已完结
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study
4个月前
已完结
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
4个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
4个月前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
4个月前
已完结
Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma
4个月前
已完结
皖公网安备34019202002308
